S&P Futures
3,894.25 -9.50 (-0.24%) Dow Futures
31,372.00 -49.00 (-0.16%) Nasdaq Futures
12,004.25 -36.25 (-0.30%) Russell 2000 Futures
1,767.50 -2.30 (-0.13%) Crude Oil
110.95 +1.38 (+1.26%) Gold
1,825.80 +1.00 (+0.05%)
SELLAS Life Sciences Group, Inc. (SLS)
Chart Events
Performance Outlook
| Previous Close | 2.3600 |
| Open | 2.4000 |
| Bid | 2.2000 x 800 |
| Ask | 2.3600 x 800 |
| Day's Range | 2.2400 - 2.4000 |
| 52 Week Range | 2.1000 - 15.0800 |
| Volume | |
| Avg. Volume | 306,837 |
| Market Cap | 47.643M |
| Beta (5Y Monthly) | 1.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.2270 |
| Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.25 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SLS
Related Research
- SELLAS Life Sciences Group, IncAnalyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat4 days agoMorningstar
- GlobeNewswire
SELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial
- No Dose-Limiting Toxicities Observed in Lymphoma and Acute Myeloid Leukemia Patients at All Dose Levels Studied To-Date - - Early Indications of Efficacy in Assessable Patients at Multiple Dose Levels - NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provided a clinical update on the
- Benzinga
SELLAS Life Sciences's Galinpepimut/Opdivo Combo Shows Increased Survival In Mesothelioma Patients
SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced updated data from a Phase 1 clinical trial of galinpepimut-S (GPS), combined with Bristol-Myers Squibb Co's (NYSE: BMY) nivolumab (Opdivo) in with malignant pleural mesothelioma (MPM). The trial included patients who were either refractory or relapsed after at least one line of the standard of care therapy. Data from eight patients enrolled in the study have been analyzed, with final data in the clinical trial expected by the end of 2022. Al
- GlobeNewswire
SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo
Median Overall Survival of 45.7 Weeks for Patients Treated With Combination Therapy for at Least One Month; Median Overall Survival in Relapsed/Refractory Patients Treated with Standard of Care is Approximately 28 WeeksNEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications, today announced encouraging update
